Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome.

Caponetti GC, Dave BJ, Perry AM, Smith LM, Jain S, Meyer PN, Bast M, Bierman PJ, Bociek RG, Vose JM, Armitage JO, Aoun P, Fu K, Greiner TC, Chan WC, Sanger WG, Weisenburger DD.

Leuk Lymphoma. 2015;56(11):3082-9. doi: 10.3109/10428194.2015.1034699. Epub 2015 May 12.

PMID:
25827211
2.

The great masquerader of malignancy: chronic intestinal pseudo-obstruction.

Taverna JA, Babiker HM, Yun S, Bishop MC, Lau-Braunhut S, Meyer PN, Enzler T.

Biomark Res. 2014 Dec 5;2(1):23. doi: 10.1186/s40364-014-0023-y. eCollection 2014.

3.

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, Scott DW, Tan KL, Steidl C, Sehn LH, Chan WC, Iqbal J, Meyer PN, Lenz G, Wright G, Rimsza LM, Valentino C, Brunhoeber P, Grogan TM, Braziel RM, Cook JR, Tubbs RR, Weisenburger DD, Campo E, Rosenwald A, Ott G, Delabie J, Holcroft C, Jaffe ES, Staudt LM, Gascoyne RD.

J Clin Oncol. 2012 Oct 1;30(28):3452-9. Epub 2012 Jul 30.

4.

A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma.

Perry AM, Cardesa-Salzmann TM, Meyer PN, Colomo L, Smith LM, Fu K, Greiner TC, Delabie J, Gascoyne RD, Rimsza L, Jaffe ES, Ott G, Rosenwald A, Braziel RM, Tubbs R, Cook JR, Staudt LM, Connors JM, Sehn LH, Vose JM, López-Guillermo A, Campo E, Chan WC, Weisenburger DD.

Blood. 2012 Sep 13;120(11):2290-6. doi: 10.1182/blood-2012-05-430389. Epub 2012 Jun 26.

5.

BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.

Iqbal J, Meyer PN, Smith LM, Johnson NA, Vose JM, Greiner TC, Connors JM, Staudt LM, Rimsza L, Jaffe E, Rosenwald A, Ott G, Delabie J, Campo E, Braziel RM, Cook JR, Tubbs RR, Gascoyne RD, Armitage JO, Weisenburger DD, Chan WC.

Clin Cancer Res. 2011 Dec 15;17(24):7785-95. doi: 10.1158/1078-0432.CCR-11-0267. Epub 2011 Sep 20.

6.

The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.

Meyer PN, Fu K, Greiner T, Smith L, Delabie J, Gascoyne R, Ott G, Rosenwald A, Braziel R, Campo E, Vose J, Lenz G, Staudt L, Chan W, Weisenburger DD.

Am J Clin Pathol. 2011 Jan;135(1):54-61. doi: 10.1309/AJCPJX4BJV9NLQHY.

PMID:
21173124
7.

Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab.

Meyer PN, Fu K, Greiner TC, Smith LM, Delabie J, Gascoyne RD, Ott G, Rosenwald A, Braziel RM, Campo E, Vose JM, Lenz G, Staudt LM, Chan WC, Weisenburger DD.

J Clin Oncol. 2011 Jan 10;29(2):200-7. doi: 10.1200/JCO.2010.30.0368. Epub 2010 Dec 6.

8.

Chromosome 1 analysis in chromophobe renal cell carcinomas with tissue microarray (TMA)-facilitated fluorescence in situ hybridization (FISH) demonstrates loss of 1p/1 which is also present in renal oncocytomas.

Meyer PN, Cao Y, Jacobson K, Krausz T, Flanigan RC, Picken MM.

Diagn Mol Pathol. 2008 Sep;17(3):141-4. doi: 10.1097/PDM.0b013e3181577d57.

PMID:
18382368
9.

HSP90 inhibitor 17AAG causes apoptosis in ATRA-resistant acute promyelocytic leukemia cells.

Meyer PN, Roychowdhury S, Kini AR, Alkan S.

Leuk Res. 2008 Jan;32(1):143-9. Epub 2007 Jul 6.

PMID:
17617451
10.

Xp11.2 translocation renal cell carcinoma with very aggressive course in five adults.

Meyer PN, Clark JI, Flanigan RC, Picken MM.

Am J Clin Pathol. 2007 Jul;128(1):70-9.

PMID:
17580272
11.

Osseous metaplasia in diffuse large B-cell lymphoma of the kidney.

Meyer PN, Al-Masri H, Alkan S.

Am J Hematol. 2007 Apr;82(4):321-4.

12.

The enigmatic role of the hemochromatosis protein (HFE) in iron absorption.

Chorney MJ, Yoshida Y, Meyer PN, Yoshida M, Gerhard GS.

Trends Mol Med. 2003 Mar;9(3):118-25. Review.

PMID:
12657433
13.

Hemochromatosis protein (HFE) and tumor necrosis factor receptor 2 (TNFR2) influence tissue iron levels: elements of a common gut pathway?

Meyer PN, Gerhard GS, Yoshida Y, Yoshida M, Chorney KA, Beard J, Kauffman EJ, Weiss G, Chorney MJ.

Blood Cells Mol Dis. 2002 Nov-Dec;29(3):274-85.

PMID:
12547217
14.

Virulence of a Salmonella typhimurium OmpD mutant.

Meyer PN, Wilmes-Riesenberg MR, Stathopoulos C, Curtiss R 3rd.

Infect Immun. 1998 Jan;66(1):387-90.

Supplemental Content

Loading ...
Support Center